While Apis Capital's flagship fund posted stellar 2025 returns, its latest investor letter spotlights the ongoing divergence of opinion on AI pure-plays like C3.ai, where heavy investment needs clash with market expectations for profitability.
Twist Bioscience kicks off fiscal 2026 with robust growth, reporting a 17% year-over-year revenue increase to $103.7 million. The company credits its semiconductor-based DNA synthesis platform and surging demand from AI-enabled drug discovery programs as key drivers, while reiterating its path to adjusted EBITDA breakeven within the year.
Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.
Despite a recent 4.7% stock decline, Edwards Lifesciences (NYSE: EW) boasts a robust 13% Return on Equity, outperforming its industry. Yet, its modest 4.6% five-year growth rate raises questions about future potential and market valuation.
The Walt Disney Company surpassed Wall Street's revenue and earnings expectations for its fiscal first quarter, powered by strength in its streaming services and theme parks. The media giant reaffirmed its full-year forecast for double-digit profit growth, signaling confidence in its ongoing strategic transformation.
Buoyed by robust demand for its premium iPhone 17 Pro models, Apple is projected to report its highest quarterly iPhone sales increase in over four years. Analysts spotlight a pivotal AI deal with Google's Gemini as a key future growth lever, even as the tech giant navigates supply chain cost pressures.
While passive index funds track the broader market, selective stock picks can deliver outsized returns. Baidu's (NASDAQ: BIDU) shares have soared 75% in the past year, dramatically outpacing the market. This rally comes despite a significant drop in earnings, shifting investor focus towards the company's long-term strategic bets in artificial intelligence and autonomous driving.
In a strategic move emphasizing its heritage, Regal Holdings has rebranded its core manufacturing division as the historic West Bend Co., underscoring a commitment to U.S. production and Wisconsin's industrial legacy.
Facing stiff competition from synthetic fibers, the cotton industry's leading research and promotion body has created a chief marketing officer role and merged its marketing teams to drive demand across the entire supply chain.
After a punishing multi-year slump, materials stocks are showing signs of life in 2026. Dow and LyondellBasell, offering yields of 5% and 10.9% respectively, present a high-risk, high-reward proposition for income investors betting on a sector recovery.
Shares of Chinese EV maker XPeng have tumbled roughly 12% over the past month, reigniting the debate over its valuation. While long-term holders remain in profit, the recent weakness prompts a fresh look at the company's prospects amid fierce competition and its path to sustained profitability.
Nvidia's landmark plan to invest up to $100 billion in OpenAI has stalled, with executives questioning the deal's structure and OpenAI's financial discipline amid a fiercely competitive AI landscape.
The Geely-owned electric vehicle maker Polestar has secured a major $400 million equity investment from a consortium led by Sumitomo Mitsui Banking Corporation and Standard Chartered Bank, signaling crucial financial backing as it navigates a competitive market.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Chinese biotech firm Arctic Vision moves to create an integrated ophthalmology powerhouse by acquiring MDCO Technology's device business, combining drug and device expertise to address unmet needs in eye care.
UBS analyst Peter Grom increased his price target for Kimberly-Clark (KMB) to $110, citing steady core performance despite lingering Kenvue-related uncertainties, after the consumer goods giant reported better-than-expected quarterly profit driven by cost discipline and resilient demand.
Scotiabank has lowered its price target for Comcast (CMCSA), reflecting ongoing pressure in its core broadband business as the media giant reports higher-than-expected customer losses in Q4 and faces fierce competition from fiber and fixed-wireless rivals.
Foundation Investment Partners, through its platform Sustainable Packaging, has acquired Paper Converters, a Walterboro-based manufacturer of spiral-wound paper tubes and boards, marking a strategic consolidation in the eco-friendly packaging sector.
While Vidhance (FRA:8W50) continues to operate at a loss, its current cash reserves and manageable burn rate suggest the company has time to execute its growth strategy. However, a recent dip in revenue adds a note of caution for investors.
